SG11201811370XA - A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate - Google Patents
A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolateInfo
- Publication number
- SG11201811370XA SG11201811370XA SG11201811370XA SG11201811370XA SG11201811370XA SG 11201811370X A SG11201811370X A SG 11201811370XA SG 11201811370X A SG11201811370X A SG 11201811370XA SG 11201811370X A SG11201811370X A SG 11201811370XA SG 11201811370X A SG11201811370X A SG 11201811370XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- asfv
- georgia
- swine fever
- virus
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 6
- 208000007407 African swine fever Diseases 0.000 title abstract 4
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 241000701386 African swine fever virus Species 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 1
- 241001225774 Moira Species 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12061—Methods of inactivation or attenuation
- C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12071—Demonstrated in vivo effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property C.--.` MD 11011110111010101111101 11010101110111111011011101111011110111 OEN Organization International Bureau (10) International Publication Number 03 (43) International Publication Date ......•' WO 2018/005358 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: THE UNIVERSITY OF CONNECTICUT [US/US]; 400 C07K 14/005 (2006.01) A61K 39/12 (2006.01) Farmington Avenue, MC 6400, Farmington, Connecticut (21) International Application Number: 06032 (US). PCT/US2017/039277 (72) Inventors: BORCA, Manuel V.; 40550 Route 25, Ori- (22) International Filing Date: ent Point, New York 11957 (US). GLADUE, Douglas 26 June 2017 (26.06.2017) P.; 40550 Route 25, Orient Point, New York 06437 (US). HOLINKA-PATTERSON, Lauren G.; 40550 Route 25, (25) Filing Language: English Orient Point, New York 11944 (US). RISATTI, Guillermo R.; 61 N. Eagleville Road, Storrs, Connecticut 06498 (US). (26) Publication Language: English O'DONNELL, Vivian K.; 61 N. Eagleville Road, Storrs, (30) Priority Data: Connecticut 06269 (US). 15/200,407 01 July 2016 (01.07.2016) US (74) Agent: GOLDBERG, Joshua B.; Nath, Goldberg & Mey- (71) Applicants: THE UNITED STATES OF AMERI- er, 112 S. West Street, Alexandria, Virginia 22314 (US). CA, AS REPRESENTED BY THE SECRETARY (81) Designated States (unless otherwise indicated, for every OF AGRICULTURE [US/US]; 1400 Independence Ave. kind of national protection available): AE, AG, AL, AM, S.W., Washington, District of Columbia 20250 (US). AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (54) Title: A RATIONALLY DEVELOPED AFRICAN SWINE FEVER ATTENUATED VIRUS STRAIN PROTECTS AGAINST CHALLENGE WITH PARENTAL VIRUS GEORGIA 2007 ISOLATE Fig. 1A : 40 50 .218W-0 RELKLTAIFFS OAPSIIKEK26 AIOWILME OLPCTRCTIO AFSTI1PKNPT, Malay/ Li1-20/1 , 7 T G Pma 18 A , R Pr5 18 Killaan3 19 I , Crl Cr3 Tengam1I82) Fair...W/95A 21 Wildabeaalaagte 18 Kiaak.,1(84) 22 Vintarla Falls Lairs (67) 2 rIganda(61) 2 L70 K./5 2 Haiti apan0ar(51) La Cranja(63) Liabon(50) Lea(35) . •I•.. I 00 90 100 110 120 ASFV-0 2 TLNNSE WrFAFENNV14 KILLNKKUSW 8152KNITE08 ILKTIKvOiT DvicAw8KL. malawi Li1-20/1 17 K N Fra 18 . Pr5 18 Killean3 K 19 Cri in Cr3 Tangani(52) Fairfield/96/1 21 Wild.haaalaagta 18 almakma(64) 22 Viat.ria Palls Moira (67) 178anda(51) E70 E75 Haiti Spencer 151) , Im Cranja(03/ 2 11 Liahon(60) Lae (35) GC (57) : African swine fever virus (ASFV) is the etiological agent of a contagious, often lethal viral disease of domestic pigs. imr) The control of African Swine Fever (ASF) has been hampered by the unavailability of vaccines. Experimental vaccines have been en k i n derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only C:::: ) successful when protecting against homologous viruses. We have constructed a recombinant A9GL/AUK virus derived from the highly 0 --.... virulent ASFV Georgia 2007 (ASFV-G) isolate by deleting the specific virulence-associated 9GL (B119L) and the UK (DP96R) genes. GC ,- 1 In vivo, ASFV-G A9GL/AUK administered intramuscularly to swine even at relatively high doses (10 6 HAD50) does not induce disease. 0 N C [Continued on next page] WO 2018/005358 Al MIDEDIMOMOIDEIREEMOOVIREINIMMEHOM CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) Importantly, animals infected with 10 4 or 10 6 HAD 5 0 are solidly protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/200,407 US9808520B1 (en) | 2016-07-01 | 2016-07-01 | Rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate |
| PCT/US2017/039277 WO2018005358A1 (en) | 2016-07-01 | 2017-06-26 | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811370XA true SG11201811370XA (en) | 2019-01-30 |
Family
ID=60189680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811370XA SG11201811370XA (en) | 2016-07-01 | 2017-06-26 | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9808520B1 (en) |
| EP (1) | EP3478705B1 (en) |
| JP (1) | JP7121950B2 (en) |
| KR (1) | KR102443074B1 (en) |
| CN (1) | CN109952310B (en) |
| AU (1) | AU2017288932B2 (en) |
| BR (1) | BR112018076633A2 (en) |
| CA (1) | CA3029552A1 (en) |
| CL (1) | CL2018003769A1 (en) |
| DK (1) | DK3478705T3 (en) |
| EA (1) | EA201990085A1 (en) |
| FI (1) | FI3478705T3 (en) |
| GE (1) | GEP20207186B (en) |
| HR (1) | HRP20240254T1 (en) |
| LT (1) | LT3478705T (en) |
| MX (1) | MX2019000048A (en) |
| MY (1) | MY197376A (en) |
| PH (1) | PH12018502684A1 (en) |
| PL (1) | PL3478705T3 (en) |
| PT (1) | PT3478705T (en) |
| RS (1) | RS65124B1 (en) |
| SG (1) | SG11201811370XA (en) |
| SI (1) | SI3478705T1 (en) |
| UA (1) | UA125584C2 (en) |
| WO (1) | WO2018005358A1 (en) |
| ZA (1) | ZA201900259B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017128039A1 (en) * | 2016-01-26 | 2017-08-03 | 浙江大学 | Gene combination and use thereof |
| CN110302371B (en) * | 2019-08-21 | 2023-05-26 | 军事科学院军事医学研究院军事兽医研究所 | Use of inactivated ASFV as immune toxin-counteracting protective component of composite vaccine |
| US11007263B2 (en) | 2019-09-24 | 2021-05-18 | The United States Of America, As Represented By The Secretary Of Agriculture | Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L |
| JP7382628B2 (en) * | 2019-10-11 | 2023-11-17 | 国立研究開発法人農業・食品産業技術総合研究機構 | Method for producing and detecting African swine fever virus |
| CN110760617B (en) * | 2019-11-26 | 2021-12-21 | 华中农业大学 | Real-time fluorescent PCR primer probe combination and kit for detecting African swine fever virus wild virus |
| KR20210087810A (en) | 2020-01-03 | 2021-07-13 | 주식회사 중앙백신연구소 | A novel vaccine composition for preventing and treating african swine fever virus |
| CN111925994B (en) * | 2020-07-03 | 2023-05-26 | 中国农业科学院兰州兽医研究所 | Recombinant African swine fever virus with DP71L gene deleted and preparation method and application thereof |
| CN112063592A (en) * | 2020-07-10 | 2020-12-11 | 中国农业科学院兰州兽医研究所 | Construction of African swine fever polygene combined deletion attenuated strain and application of attenuated strain as vaccine |
| CN111748563A (en) * | 2020-07-10 | 2020-10-09 | 中国农业科学院兰州兽医研究所 | Construction of African swine fever gene deletion low virulent strain and application of African swine fever gene deletion low virulent strain as vaccine |
| CN111996175B (en) * | 2020-09-04 | 2023-11-21 | 军事科学院军事医学研究院军事兽医研究所 | African swine fever attenuated and live vaccine deleted of E66L, I267L gene |
| WO2022107793A1 (en) * | 2020-11-20 | 2022-05-27 | 国立研究開発法人農業・食品産業技術総合研究機構 | Immortalized pig-fetus small-intestinal macrophages |
| EP4267965A1 (en) | 2020-12-24 | 2023-11-01 | Intervet International B.V. | African swine fever diva immunoassay |
| CN112852761B (en) * | 2021-03-08 | 2022-08-23 | 中国农业科学院兰州兽医研究所 | Construction of gene deletion attenuated African swine fever virus strain and application of gene deletion attenuated African swine fever virus strain as vaccine |
| CN114392345B (en) * | 2021-03-11 | 2023-08-25 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | Application and method of E199L protein in promoting apoptosis |
| CN113061588B (en) * | 2021-05-20 | 2023-08-01 | 军事科学院军事医学研究院军事兽医研究所 | African swine fever virus attenuated strain deleted of I226R gene and live vaccine thereof |
| US11801296B2 (en) | 2021-06-30 | 2023-10-31 | The United States Of America, As Represented By The Secretary Of Agriculture | Development of a novel live attenuated African swine fever vaccine based in the deletion of gene A137R |
| CN114107228B (en) * | 2021-11-11 | 2023-06-13 | 中国农业科学院兰州兽医研究所 | Construction of attenuated African swine fever virus strain with twelve genes deleted and application of attenuated African swine fever virus strain as vaccine |
| CN113831394B (en) * | 2021-11-29 | 2022-04-12 | 中国人民解放军军事科学院军事医学研究院 | Recombinant virus combination of African swine fever virus ASFV gene and vaccine prepared from recombinant virus combination |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8610106D0 (en) * | 1986-04-25 | 1986-05-29 | Central Blood Lab Authority | Human igm-producing heterohybridoma |
| US8846055B2 (en) * | 2006-05-30 | 2014-09-30 | The United States Of America, As Represented By The Secretary Of Agriculture | Virulence determinant within the E2 structural glycoprotein of classical swine fever virus |
| US9352032B2 (en) * | 2014-03-07 | 2016-05-31 | The United States Of America As Represented By The Secretary Of Agriculture | Live attenuated antigenically marked classical swine fever vaccine |
| GB201410971D0 (en) * | 2014-06-19 | 2014-08-06 | Pirbright Inst The | Vaccine |
| US9463234B2 (en) * | 2014-09-24 | 2016-10-11 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated african swine fever virus strain induces protection against challenge with homologous virulent parental virus georgia 2007 isolate |
| US9528094B2 (en) * | 2014-11-10 | 2016-12-27 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated African swine fever virus vaccine based in the deletion of MGF genes |
-
2016
- 2016-07-01 US US15/200,407 patent/US9808520B1/en active Active
-
2017
- 2017-06-26 PT PT178210084T patent/PT3478705T/en unknown
- 2017-06-26 GE GEAP201714984A patent/GEP20207186B/en unknown
- 2017-06-26 WO PCT/US2017/039277 patent/WO2018005358A1/en unknown
- 2017-06-26 MX MX2019000048A patent/MX2019000048A/en unknown
- 2017-06-26 BR BR112018076633-0A patent/BR112018076633A2/en unknown
- 2017-06-26 RS RS20240124A patent/RS65124B1/en unknown
- 2017-06-26 UA UAA201900970A patent/UA125584C2/en unknown
- 2017-06-26 MY MYPI2018002721A patent/MY197376A/en unknown
- 2017-06-26 SI SI201731488T patent/SI3478705T1/en unknown
- 2017-06-26 EP EP17821008.4A patent/EP3478705B1/en active Active
- 2017-06-26 HR HRP20240254TT patent/HRP20240254T1/en unknown
- 2017-06-26 AU AU2017288932A patent/AU2017288932B2/en active Active
- 2017-06-26 LT LTEPPCT/US2017/039277T patent/LT3478705T/en unknown
- 2017-06-26 KR KR1020197003279A patent/KR102443074B1/en active IP Right Grant
- 2017-06-26 CN CN201780053651.9A patent/CN109952310B/en active Active
- 2017-06-26 PL PL17821008.4T patent/PL3478705T3/en unknown
- 2017-06-26 CA CA3029552A patent/CA3029552A1/en active Pending
- 2017-06-26 DK DK17821008.4T patent/DK3478705T3/en active
- 2017-06-26 FI FIEP17821008.4T patent/FI3478705T3/en active
- 2017-06-26 EA EA201990085A patent/EA201990085A1/en unknown
- 2017-06-26 SG SG11201811370XA patent/SG11201811370XA/en unknown
- 2017-06-26 JP JP2018568233A patent/JP7121950B2/en active Active
-
2018
- 2018-12-19 PH PH12018502684A patent/PH12018502684A1/en unknown
- 2018-12-21 CL CL2018003769A patent/CL2018003769A1/en unknown
-
2019
- 2019-01-15 ZA ZA2019/00259A patent/ZA201900259B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9808520B1 (en) | 2017-11-07 |
| ZA201900259B (en) | 2019-09-25 |
| JP7121950B2 (en) | 2022-08-19 |
| AU2017288932A1 (en) | 2019-02-14 |
| EP3478705A4 (en) | 2020-04-29 |
| CN109952310A (en) | 2019-06-28 |
| LT3478705T (en) | 2024-02-26 |
| HRP20240254T1 (en) | 2024-05-10 |
| WO2018005358A1 (en) | 2018-01-04 |
| CL2018003769A1 (en) | 2019-03-22 |
| JP2019520827A (en) | 2019-07-25 |
| BR112018076633A2 (en) | 2019-04-24 |
| SI3478705T1 (en) | 2024-04-30 |
| KR20190018020A (en) | 2019-02-20 |
| KR102443074B1 (en) | 2022-09-14 |
| DK3478705T3 (en) | 2024-02-26 |
| EP3478705B1 (en) | 2023-11-29 |
| GEP20207186B (en) | 2020-11-25 |
| RS65124B1 (en) | 2024-02-29 |
| FI3478705T3 (en) | 2024-02-21 |
| CN109952310B (en) | 2023-05-23 |
| EP3478705A1 (en) | 2019-05-08 |
| MY197376A (en) | 2023-06-14 |
| GEAP201714984A (en) | 2020-08-10 |
| PH12018502684A1 (en) | 2019-04-15 |
| MX2019000048A (en) | 2019-07-04 |
| AU2017288932B2 (en) | 2022-06-09 |
| UA125584C2 (en) | 2022-04-27 |
| PT3478705T (en) | 2024-02-01 |
| PL3478705T3 (en) | 2024-04-15 |
| EA201990085A1 (en) | 2019-05-31 |
| CA3029552A1 (en) | 2018-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811370XA (en) | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| Diallo et al. | The threat of peste des petits ruminants: progress in vaccine development for disease control | |
| SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| SG11201903460QA (en) | Lipid nanoparticle mrna vaccines | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201810549TA (en) | Hiv vaccine formulation | |
| SG11201903411YA (en) | Anti-p53 antibodies | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201901457TA (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| Calero-Bernal et al. | Congenital toxoplasmosis in wild boar (Sus scrofa) and identification of the Toxoplasma gondii types involved | |
| SG11201808809PA (en) | Therapeutic hpv vaccine combinations | |
| SG11201900912PA (en) | Novel fish pathogenic virus | |
| SG11201810299SA (en) | Multivalent vaccines against major swine viral diseases |